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Introduction 42 
 The scientific community has continuously advanced promising treatment concepts for 43 
cell-based therapies in stroke. These approaches principally aim to modulate post-ischemic 44 
immune responses and augment endogenous repair. Another aim currently under study at the 45 
bench level is to transplant new tissue and restore neural circuits. Many stem and non-stem cell 46 
populations have shown encouraging efficacy in preclinical models, and selected types of cell 47 
therapies are currently undergoing testing in clinical trials.1-4  48 
Recent mechanistic studies have tremendously advanced our understanding of the 49 
different parameters that influence experimental stroke therapies. While cell therapies offer 50 
unprecedented therapeutic time window expansions of days to weeks (and possibly even 51 
months to years after stroke), there are several potential factors that may affect their impact. 52 
These include age5, comorbidities6,7, concurrent medications8, and even chronobiological 53 
mechanisms.9 In theory, thorough preclinical research should take into account all of these 54 
factors or at least their most relevant combinations. However, budgetary constraints, the lack 55 
of adequate in vitro and in vivo models, and the enormous amount of time required to address 56 
the multitude of relevant factors severely impairs such attempts in research practice. This 57 
dilemma affects current and future translational work and thus requires careful consideration.  58 
The Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) meetings have 59 
regularly brought together academic and industry leaders and experts from regulatory 60 
authorities to discuss the latest developments in cell therapies for stroke and to publish 61 
recommendations for preclinical and clinical research.10-12 The fourth STEPS meeting aimed to 62 
update previous preclinical guidelines with respect to novel stroke models, biomaterials, and 63 
advanced approaches combining cell therapies with biomaterials, drugs, or neurorehabilitation. 64 
STEPS delegates further provide new recommendation on preclinical study designs including 65 
multi-center preclinical trials (MCPTs) and suggest a strategy to accelerate and improve clinical 66 
translation of cell therapies for stroke without sacrificing scientific rigor and patient safety. This 67 
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can be achieved by a close interlink of preclinical and clinical studies while targeting particular 68 
stroke patient subpopulations. Main recommendations are summarized at the end of the STEPS 69 
4 report.  70 
 71 
Part I: Updated preclinical guidelines  72 
Stroke model selection in the era of recanalization therapies 73 
We recommend selecting models that best represent the clinical population targeted with 74 
a particular cell therapy. The recent advent of mechanical thrombectomy has changed the 75 
clinical landscape, and the application of cell therapies are discussed directly after 76 
recanalization.13 Transient models should be selected when investigating this scenario. The 77 
filament model is widely used to represent mechanical recanalization14; however, its use for 78 
long-term studies poses some limitations due to large infarcts associated with high mortality.15  79 
Thromboembolization followed by thrombolysis is a clinically important model for testing cell 80 
therapies in the context of thrombolysis.16 Moreover, reperfusion is often incomplete in patients 81 
undergoing thrombolytic therapy or spontaneous recanalization. This is also observed in 82 
spontaneously hypertensive rats that can serve as a model for these conditions17 while also 83 
exhibiting other important stroke comorbidities. Total reperfusion failure or persistent 84 
occlusion can be modelled by permanent MCAO.  85 
 86 
Large animal models 87 
The gyrencephalic brain featured by large animal modes (LAMs) is bigger than the 88 
rodent brain and more suitable for sophisticated clinical imaging approaches.18,19 Grey-to-89 
white-matter ratio approximates that of humans.9 LAMs allow more realistic and precise testing 90 
of cell delivery techniques including stereotaxic and intra-arterial cell administration, and dose 91 
translation to human clinical trials. Cell migration and paracrine effects, as in the human brain, 92 
are challenged by larger anatomic distances. LAMs are also suitable to investigate stroke 93 
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sequelae such as cognitive impairment and decline20, and are further recommended to assess 94 
the value of potential biomarkers indicating cell therapy safety and efficacy. 95 
On the other hand, LAM studies typically involve smaller sample sizes as they are more 96 
expensive and require dedicated infrastructure. Major endpoints including functional outcome 97 
and lesion size tend to be more variable than in standardized rodent studies. Although 98 
resembling the situation in human patient cohorts, these issues can significantly reduce study 99 
power.21 LAMs are therefore of limited use in exploratory cell therapy studies. Meaningful 100 
LAM experiments require a precise understanding of the addressed endpoint(s), as well as of 101 
sample and effect sizes. Nevertheless, LAMs are highly valuable translational tools when 102 
considering their limitations and employing them in well-planned confirmative studies.11 103 
Funding bodies are encouraged to support research using LAMs in such scenarios, particularly 104 
when critical information on patient safety and delivery route efficiency can be obtained. 105 
 106 
Sex differences, age, and comorbidities  107 
In line with previous recommendations11,12, the STEPS group recommends testing cell 108 
therapies in animal models of different age, sex, and comorbidities. However, we also recognize 109 
that modeling these variables, especially comorbidities, has limitations due their multitude and 110 
complexity. The impact of these factors might be better investigated in large phase III clinical 111 
trials allowing for sub-hoc analyses of patient populations with respective comorbidity profiles, 112 
or in MCPTs combining the capacities of many labs. An alternative approach (outlined in part 113 
III) is to focus on stroke patient subpopulations with particular stroke configuration and 114 
comorbidity profiles, and to design preclinical studies accordingly.  115 
 116 
Dose escalation studies: novel implications 117 
In line with previous recommendations10,11 and in light of the neutral results from the 118 
MASTERS (multipotent adult progenitor cells given intravenously, NCT01436487) and 119 
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ACTISSIMA (SB623 administered intracerebrally, NCT02448641) trials that may partially be 120 
related to dosing issues, the STEPS group continues to recommend efficacy-focused preclinical 121 
dose escalation studies for all routes of administration. Intra-arterial administration of cells may 122 
cause microvascular obstruction under certain circumstances.22 Hence, dose escalation studies 123 
are not only important for preclinical efficacy assessments, but are highly recommended when 124 
assessing safety aspects. This particularly accounts for intra-arterial or more invasive 125 
application routes. Methods capable of predicting the target territory of cell infusions may help 126 
to optimize the safety profile. LAMs may be suitable to simulate clinical transplantation 127 
scenarios regarding vessel dimensions and imaging-based surveillance.23  128 
 129 
Drug-cell interactions  130 
 It is likely in clinical scenarios that patients receiving cell therapy also receive 131 
medications for stroke comorbidities and for secondary prevention. Cell therapies may further 132 
be combined with pharmacological treatments to enhance their therapeutic impact.24 Given the 133 
paracrine effects of many cell therapies, interactions between drugs and cells cannot be 134 
excluded. This important aspect requires careful consideration when moving towards the clinic, 135 
but little is known about these potential interactions. Detrimental effects were seen when 136 
combining granulocyte-colony stimulating factor and bone marrow mononuclear cells, each of 137 
which is effective as a stand-alone treatment in rodents.25,26 On the other hand, synergistic 138 
effects have been reported for the combination of cell therapies with other commonly prescribed 139 
medication such as statins.27 140 
The STEPS 4 group recommends more research on potential drug-cell interactions in 141 
appropriate in vitro and in in vivo test systems. Drug classes being predominantly used in stroke 142 
patients, such as antiplatelets, anti-hypertensive, and statins, should be the main focus. We 143 
further suggest testing on autologous cell preparations when applied in patients receiving 144 
multiple medications. These tests can be tailored to the medication profile of individual patients. 145 
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 146 
Biomaterials 147 
Biomaterials are increasingly being incorporated for the delivery of cells to reduce shear 148 
stress induced by needle injections28,29 but also to provide factors that improve post-149 
transplantation cell survival.30,31 Scaffolds can support transplanted cells inside the lesion 150 
cavity32 by providing structural cues and biochemical signals.33,34 Post-stroke tissue 151 
restoration35, and a guided neuronal differentiation36 can be achieved using biomaterials 152 
engineered to release growth factors, mediators of angiogenesis, or immunomodulators in a 153 
temporal sequence and without exerting systemic side effects.37-39 A systematic optimization of 154 
a hydrogel, for instance, improved the survival of human neural stem cells implanted into the 155 
stroke-damaged brain and controlled their differentiation. However, it remains unclear if the 156 
combined use of biomaterials and cells will transfer to further improvements in functional 157 
recovery. To date, most studies combining biomaterials and cells for transplantation are of an 158 
exploratory rather than definitive/confirmative nature. We therefore recommend long-term 159 
studies to investigate the safety and efficacy profile of biomaterial applications once a basic 160 
therapeutic benefit has been shown. LAMs may help to optimize application procedures. Early 161 
involvement of regulatory authorities, ideally already during early-stage preclinical research, is 162 
recommended, as biomaterial-cell combinations are challenging from a regulatory perspective. 163 
 164 
Neurorehabilitation 165 
Most stroke survivors receive some form of rehabilitation. Thus, neurorehabilitation is 166 
important to consider when developing cellular therapies for stroke. Indeed, treadmill running 167 
and intravenous delivery of mesenchymal stem cells together improve behavioral recovery in 168 
animals with ischemic stroke.40,41 Timing of such combination therapy is crucial when targeting 169 
stroke recovery as there is a sensitive phase for neurorehabilitation (Fig. 1A). It is possible that 170 
some cell therapies might re-open a plasticity time window in chronic stroke, and 171 
8 
 
neurorehabilitation may be beneficial in such scenarios by stabilizing the recovered functions. 172 
The recent Stroke Recovery and Rehabilitation Roundtable (SRRR)-115 and SRRR-242 173 
recommendations are valuable in designing preclinical rehabilitation studies and in improving 174 
clinical translation. However, as in the case of comorbidities, including rehabilitation renders 175 
study designs complex and difficult to implement. Also, the effects of add-on 176 
neurorehabilitation should be discriminated from stand-alone cell therapies, which may be 177 
challenging as shown recently with adipose tissue-derived stem cells and enriched 178 
environments.43 Routine investigation of cell therapy in combination with neurorehabilitation 179 
is recommended when significant additional therapeutic effects are expected from this 180 
combination, or when the combination is a central mode of action.  181 
 182 
Part II: New considerations on preclinical study designs 183 
Potential new models and targets: lacunar, white matter, and hemorrhagic strokes 184 
 Most preclinical studies model large territorial infarcts. However, other important 185 
clinical target populations are patients with smaller infarcts in the subcortical grey and white 186 
matter. Importantly, the smaller volume of the infarct and the preservation of some anatomical 187 
tissue structures may foster repair.44 Small deep white matter infarcts may be particularly 188 
suitable for cells (e.g. glial progenitors) capable of or intended for tissue restoration45 and might 189 
be responsive to cell-borne local paracrine mechanisms. We recommend to consider such stroke 190 
types (see supplementary table) as alternative targets to large territorial infarcts and/or when 191 
working on tissue-restorative cell therapies.  192 
 Intracerebral hemorrhage (ICH)46 involves pathogenic mechanisms that may provide 193 
novel cell therapy targets. Hemoglobin breakdown products (HBPs), such as hemin, damage 194 
axons and induce ferroptosis and necroptosis in distant, primarily intact neuronal somata.47 195 
These processes might be mitigated or reversed by factors released from therapeutic cells. 196 
Smaller hemorrhagic lesions or damage caused by HBPs may also be promising targets for 197 
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tissue regeneration approaches. Furthermore, peripheral and central inflammatory processes 198 
also contribute to further brain injury after ICH and these mechanisms might make excellent 199 
targets for some cell-based therapies. 200 
 201 
Preconditioning of cell transplants 202 
 Long-term survival of transplanted cells is an important aspect for approaches that target 203 
long-term engraftment of neural stem cells to support or repair damaged neuronal circuits, or 204 
for which long-term trophic support is required. While cell survival has been poor in most 205 
previous studies, recent advantages were made in the field of cell preconditioning.48,49 These 206 
techniques can significantly enhance and/or prolong survival of transplanted cells and should 207 
be considered for approaches that may benefit thereof.   208 
 209 
Behavioral readout parameter selection 210 
Functional tests should be sensitive to detect long-term impairment and treatments 211 
effects, but not be affected by repeated testing or compensation.20 Various reaching tasks, foot 212 
fault, cylinder and adhesive tests provide quantitative and objective assessment in efficacy 213 
studies.15 Simpler tasks can overestimate treatment effects but are valuable for exclusion of 214 
stroke animals with no/minor impairment, stratification regarding impairment severity, and 215 
treatment assessment during the acute phase. Appropriate tests should be selected for the 216 
respective stroke model, species, scenario, and study duration (Fig. 1B).  217 
Smaller lesions require particularly sensitive and precise behavioral outcome measures. 218 
These lesions are more sensitive for functional compensation/spontaneous recovery and 219 
impairments may be masked. Automated readout systems carry high specificity and sensitivity 220 
and are being increasingly used in neurodegenerative disorders with initial subtle motor 221 
deficits.50 The supplementary table summarizes information on specific deficits and their 222 
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measurement in lacunar lesions. Lastly, cognitive impairment and depression are common 223 
stroke complications, but at present there is no consensus on which tests to use in animals. 224 
 225 
Safety assessments as a focus 226 
Definitive demonstration of safety across multiple preclinical endpoints will be an invaluable 227 
resource when advancing cellular therapies for stroke treatment. The cell administration site 228 
should be evaluated for signs of inflammation or edema as well as acute respiratory problems 229 
for intravenous delivery to ensure the cell therapy is not inducing local or systemic immune 230 
responses. This may include animals with a humanized immune system. When performing 231 
repetitive administration of a cells, recipient sensitization (e.g., by lymphocyte proliferation 232 
assays), indicating adaptive immune system activation, should be contemplated.  233 
Short- and long-term biodistribution and possible cell engraftment should be evaluated 234 
to determine cell persistence, particularly if the intended goal is engraftment. However, cell 235 
types exerting paracrine and immunomodulatory mechanisms, or exogenous cells may not 236 
persist which is viewed as an attractive component of approaches for which cell survival is not 237 
necessarily required. Complete endpoint evaluations of tissues and organ systems should be 238 
performed to definitively demonstrate that the cell administration does not have any off-target 239 
effects. Abnormal tissue growth, tumorigenesis or aberrant ectopic fiber sprouting should be 240 
excluded when using pluripotent stem cells or other cell types with high proliferation, 241 
differentiation, and fiber projection capabilities.  242 
 243 
Multicenter trials  244 
 Innovative preclinical study designs including MCPTs have been proposed since the last 245 
STEPS recommendations. MCPTs mimic the design of large scale, efficacy-centered clinical 246 
trials with rigorous implementation of quality assurance measures as performed in clinical 247 
research.51 MCPTs are believed to enhance predictive value and statistical power in preclinical 248 
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research, and to provide a close-to-practice assessment of the potential treatment. They may be 249 
of particular value when assessing cell therapies with mild to moderate impact on stroke (i.e. 250 
improvements of 10 to 20%)52 or when assessing the impact of multiple therapy-influencing 251 
factors. MCPTs can also help to verify the benefit of combination therapies. This requires 252 
greatly enhanced statistical power to discriminate the effect of the combination from the impact 253 
of the individual therapies (e.g., rehabilitation plus cell therapy). The MCPT concept has been 254 
well received throughout the stroke community53,54, and first MCPTs revealed effect sizes being 255 
considerably lower than what would have been expected from standard single center preclinical 256 
studies.55  257 
However, MCPTs are more challenging to harmonize and carry much higher costs than 258 
standard study designs. Industry may benefit from MCPTs prior to initiating a clinical study.56 259 
The STEPS 4 consortium recommends considering MCPTs as an option when planning a 260 
translational research program in cell therapy for stroke. Importantly, NIH recently supported 261 
the creation of MCPTs and has launched the Stroke Preclinical Assessment Network (SPAN) 262 
program currently focused on multicenter evaluations of acute neuroprotectants as a 263 
complementary treatment to recanalization. Industry participation is highly encouraged in 264 
SPAN. Experience from the program will be invaluable to learn how MCPTs can be organized 265 
best to fully benefit from the enhanced power in assessing complex treatments, and how the 266 
complex logistics of MCPTs can be mastered. Ideally, successful SPAN activities will serve as 267 
a role model for MCPTs in cell therapies.   268 
 269 
Potency assay development and qualification 270 
 A new recommendation from the STEPS group is the development of surrogate potency 271 
assays. Demonstrating a direct measurable correlation between a cell therapy and a biomarker 272 
or another quantifiable biological process with a beneficial outcome is critical to monitor the 273 
hypothesized mechanism of action. Biomarkers for putative mechanisms of action are also 274 
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critical to regulators for late stage clinical trial authorization. Biomarkers might be used to 275 
develop potency assays that should be robust, specific, informative, and reproducible in 276 
describing a fundamental biological effect of the expected benefit. Qualified potency assays are 277 
“locked down” as part of phase III clinical testing. They need to be transferred and performed 278 
under Good Manufacturing Practice (GMP) conditions before officially filing for product 279 
approval with the Food and Drug Administration in the United States. The development of 280 
potency assays during preclinical animal testing is therefore paramount prior to moving cellular 281 
therapies into advanced stages of clinical trials. As hypotheses change to reflect advances in the 282 
fundamental understanding of how cellular therapies provide benefit, new potency assays 283 
should be developed to parallel our understanding of cell-mediated benefits. For example, given 284 
increasing studies showing how many cell therapies target immune responses after stroke, 285 
immunomodulation may be an important potency assay for some cell therapies.57 286 
 287 
Part III: Concepts for accelerating and improving preclinical research 288 
Rethinking content and sequence of preclinical and clinical trials 289 
State of the art preclinical research on cell therapy safety and efficacy takes significant 290 
time and resources. The broad and increasing spectrum of potential confounders is expected to 291 
engender additional budgetary and temporal demands that may severely hamper clinical 292 
translation. STEPS 4 discussed options to accelerate preclinical research while giving 293 
consideration to the complexity of potential confounding factors. A promising concept is to 294 
more clearly discriminate exploratory and confirmatory preclinical research58, and to rigorously 295 
distinguish the primary goals of phase I/II clinical trials (safety) from later phases (efficacy). 296 
This allows a well-orchestrated sequence of preclinical and clinical tests with partially parallel 297 
workflows (Fig. 2). 298 
 Once a cell therapeutic paradigm is identified in initial exploratory studies, research 299 
activities are divided into two parallel tracks. First, exploratory research in standard rodent 300 
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stroke models confirms basic efficacy. Second, confirmative research investigates safety. This 301 
should also consider the most important comorbidities in the expected patient population, risks 302 
exhibited by the approach and the intended route of administration.59 Thorough confirmation 303 
of safety and basic efficacy then allows proceeding to a phase I/IIa clinical trial which should 304 
not have a major focus on efficacy endpoints, but would be powered to confirm safety. 305 
Moreover, it should identify predominant profile characteristics of the targeted patient 306 
population such as type and frequency of comorbidities, infarct location and size, and co-307 
medications.  308 
This information is used to design advanced preclinical efficacy tests tailored to the 309 
target patient population profile. Ideally, these efficacy studies would be conducted in parallel 310 
to the phase I/IIa study. They may also be designed to identify subgroups with a pronounced 311 
benefit from the particular cell therapy which can be considered in a subsequent phase IIb/III 312 
clinical trial. 313 
This approach has three major advantages: First, basic and enhanced preclinical efficacy 314 
studies can be organized in parallel to preclinical or clinical safety tests, saving valuable time. 315 
Second, the sequence of investigations in animal models and patients yields important data that 316 
will help to identify the most suitable patient populations for efficacy-driven clinical trials. 317 
Third, more thorough preclinical efficacy data can be used to design GMP potency assays with 318 
a higher predictive value than commonly applied ones.  319 
 320 
Cell therapy responders versus non-responders 321 
The STEPS 4 working group recommends storage of tissues and samples from animals 322 
that both respond and do not respond to cell therapy. As we learn more about the mechanisms 323 
of action through which cell therapies provide benefit, we may be able to retrieve stored samples 324 
from previous experiments to compare if preclinical responders and non-responders differ 325 
regarding newly identified or proposed biomarkers or pathways. This enables to refine our 326 
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clinical understanding of “responders” or “non-responders” and to better identify patients who 327 
can optimally benefit. 328 
 329 
Preclinical data sharing platforms 330 
 A complementary opportunity to handle the increasing complexity of preclinical data 331 
are (open) sharing platforms. STEPS 4 participants unanimously agreed that such platforms, 332 
also including information from cell therapy cases in patients, are beneficial. Data would be 333 
available for benchmarking against other research programs, enhance study power, and 334 
facilitate meta-analyses. A central registry and predefinition of common preclinical data 335 
elements are required, but can be informed by existing clinical registries. The Collaborative 336 
Approach to Meta-Analysis and Review of Animal Data from Experimental Studies 337 
(CAMRADES) database is an excellent role model, although a cell therapy registry for stroke 338 
must reflect the specific requirements of the community in detail. 339 
 Original data may be sensitive when related to pending intellectual property or 340 
commercial interests. Industry leaders among the STEPS 4 group stressed that such data should 341 
enjoy special protection, but is not necessarily excluded from sharing. For instance, the identity 342 
of a sensitive cell product could be concealed, but cell-treated subjects as well as all insensitive 343 
information on the cell product can be disclosed. Contributors using highly sensitive cell 344 
products may at least provide control cases.  345 
Options to motivate contribution to data sharing platforms may be to allow access only 346 
to those who contribute and/or a general requirement that publically funded cell therapy 347 
research for stroke shall be publically. The STEPS 4 consortium suggests that decision makers 348 
at the NIH or the European Commission should consider funding schemes that help realizing 349 
data platforms tailored to cell therapies. Ideally, open data registries are organized 350 
internationally and provide connection hubs for industry and clinical cell therapy data.  351 
 352 
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Novel collaboration formats and the role of industry  353 
 The increasing complexity of preclinical stroke research and the parallel need for 354 
acceleration without sacrificing specificity and accuracy may not only require novel research 355 
strategies but also novel research alliances. Providing methodological knowhow, flexibility, 356 
and sufficient funds is required to meet the increasing need for rigor in preclinical research, 357 
raising the need for academic-industry alliances. Such alliances should not be restricted to 358 
sponsored contract research but true collaboration.56 Academic-industry collaborations are also 359 
pivotal to sustainably utilize MCPTs. Finally, the experience of industry in meeting regulatory 360 
demands, technical aspects of cell therapies, and related logistics as well as clinical trial design 361 
is invaluable to inform preclinical research in order to advance the field. The STEPS 4 group 362 
recommends long-term academic-industry partnerships to thoroughly develop cell therapeutics 363 
from bench to bedside through closer collaborations.  364 
 365 
Recommendation summary  366 
 1. A stronger focus on safety rather than confirming efficacy in early preclinical 367 
research, followed by early, safety-oriented clinical research has the potential to accelerate 368 
translational research without sacrificing quality. 369 
2. We recommend thorough and advanced safety assessments and sufficient (standard 370 
stroke model) efficacy testing to support phase I/II safety trials. Advanced preclinical efficacy 371 
testing should be tailored to match targeted patient populations. This approach addresses the 372 
increasing complexity of potential confounding factors in a reasonable time. Appropriate 373 
primary readout parameters should be chosen for subsequent phase IIb/III trials. 374 
 3. Specific stroke models should best mimic the targeted patient population. LAMs are 375 
recommended if they provide additional, crucial information for clinical translation. 376 
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 4. High priority should be given to developing specific and validated potency assays. 377 
Investigating drug-cell interactions and identifying cell therapy responders versus non-378 
responders is recommended.  379 
5. Sharing preclinical and clinical data will help the community tackle more complex 380 
research questions (e.g., whether comorbidities affect efficacy or safety).  381 
6. Confirmative MCPTs are a valuable confirmative research format, but larger research 382 
consortia including industry joint ventures are required for successful implementation. MCPTs 383 
are preferred prior to definitive efficacy trials  384 
 385 
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Cox Jr, Marcel M. Daadi, Euperio Diez Tejedor, Andrew W. Grande, María Gutiérrez-387 
Fernández, Peiman Hematti, David Hess, David Y. Huang, Zaal Kokaia, Satoshi Kuroda, 388 
Francisco P. Moniche, Keith Muir, Scott Olson, Paulo Henrique Rosado de Castro, John 389 
Sinden, Nikunj Satani, Hideo Shichinohe, Gary K. Steinberg, Piotr Walczak, Lawrence 390 
Wechsler, Franklin West, Farhaan Vahidy, Dorothy E. Vawter, Dileep R. Yavagal, Bing Yang, 391 
Ludvic Zrinzo. 392 
 393 
Disclosures 394 
As an employee of the institution, UTHealth, Dr Savitz has served in the following roles: as a 395 
site investigator in clinical trials sponsored by Athersys, Genentech, Pfizer, Dart Neuroscience, 396 
and SanBio, for which UTHealth receives payments on the basis of clinical trial contracts; as 397 
an investigator on clinical trials supported by National Institutes of Health (NIH) grants, 398 
Department of Defense, Let’s Cure CP, the Texas Institute for Rehabilitation and Research 399 
Foundation, and the Cord Blood Registry Systems; as a principal investigator on NIH-funded 400 
grants in basic science research; as principal investigator for an imaging analysis center for 401 
clinical trials sponsored by SanBio; as a consultant to Neuralstem, SanBio, Mesoblast, 402 
17 
 
ReNeuron, Lumosa, Celgene, Dart Neuroscience, BlueRock. All funding goes to the institution. 403 
Site Principal Investigator for ACTissMA clinical Trial, sponsored by San Bio, Inc., Steering 404 
Committee Member TIGER clinical trial, sponsored my RAPID Medical, Consultant to 405 
Cerenovus (Johnson & Johnson), Medtronic& Neuralanalytics (D.R.Y.); Consultant for Qool 406 
Therapeutics, Royalties from Peter Lazic US, and consultant for NeuroSave (GKS). Chief 407 
Investigator for PISCES 1 and PISCES 2 trials, consultancy, advisory board with ReNeuron 408 
(KM). Sponsored research agreements with Athersys, CBR Systems Inc, Hope Bio, and 409 
Biostage (SDO). Honoraria as a speaker or member of advisory boards or travel grants from 410 
Boehringer-Ingelheim, Bristol-Myers-Squibb, Pfizer, Bayer, Daichii-Sankyo and Novartis 411 
(Exuperio Díez Tejedor). Sponsored research from National Institutes of Health, 412 
USAMMRA/DOD, State of Texas ETF, CBR, Inc., Athersys, Inc., Celgene Cellular 413 
Therapeutics. Cellvation, Inc. Cellularity, Inc. Hope Biosciences, The Bentsen Foundation, 414 
Mission Connect, Let’s Cure CP, Ladybug Foundation and Equity/Royalty from Cellvation, 415 
Inc.; Coagulex, Inc., EMIT Corporation (CSC). Consultant to Athersys and ReNeuron (PB). 416 
  417 
18 
 
References 418 
1. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Kim AS, Johnson JN, et al. 419 
Two-year safety and clinical outcomes in chronic ischemic stroke patients after 420 
implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a 421 
phase 1/2a study. [published online November 23, 2018]. J Neurosurg. 2018. 422 
https://thejns.org/view/journals/j-neurosurg/aop/article-10.3171-423 
2018.5.JNS173147.xml. Accessed May 28, 2019. 424 
2. Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, et al. Safety and 425 
efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a 426 
randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 427 
2017;16:360-368.  428 
3. Moniche F, Rosado-de-Castro PH, Escudero I, Zapata E, de la Torre Laviana FJ, 429 
Mendez-Otero R, et al. Increasing Dose of Autologous Bone Marrow Mononuclear 430 
Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of 431 
Two Clinical Trials. Stem Cells Int. 2016;2016:8657173. 432 
4. Kalladka D, Sinden J, Pollock K, Haig C, McLean J, Smith W, et al. Human neural stem 433 
cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. 434 
Lancet. 2016;388:787-796. 435 
5. Sandu RE, Balseanu AT, Bogdan C, Slevin M, Petcu E, Popa-Wagner A. Stem cell 436 
therapies in preclinical models of stroke. Is the aged brain microenvironment refractory 437 
to cell therapy? Exp Gerontol. 2017;94:73-77. 438 
6. Möller K, Pösel C, Kranz A, Schulz I, Scheibe J, Didwischus N, et al. Arterial 439 
Hypertension Aggravates Innate Immune Responses after Experimental Stroke. Front 440 
Cell Neurosci. 2015;9:461. 441 
7. Chen J, Ye X, Yan T, Zhang C, Yang XP, Cui X, et al. Adverse effects of bone marrow 442 
stromal cell treatment of stroke in diabetic rats. Stroke. 2011;42:3551-3558. 443 
19 
 
8. Cui X, Chopp M, Zacharek A, Roberts C, Lu M, Savant-Bhonsale S, et al. Chemokine, 444 
vascular and therapeutic effects of combination Simvastatin and BMSC treatment of 445 
stroke. Neurobiol Dis. 2009;36:35-41. 446 
9. Boltze J, Nitzsche F, Jolkkonen J, Weise G, Pösel C, Nitzsche B, et al. Concise Review: 447 
Increasing the Validity of Cerebrovascular Disease Models and Experimental Methods 448 
for Translational Stem Cell Research. Stem Cells. 2017;35:1141-1153. 449 
10. Savitz SI, Cramer SC, Wechsler L, STEPS 3 Consortium. Stem cells as an emerging 450 
paradigm in stroke 3: enhancing the development of clinical trials. Stroke. 2014;45:634-451 
639. 452 
11. Savitz SI, Chopp M, Deans R, Carmichael T, Phinney D, Wechsler L, et al. Stem Cell 453 
Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke. 2011;42:825-829. 454 
12. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and 455 
clinical science for cellular and neurogenic factor therapy in treating stroke. Stem Cell 456 
Therapies as an Emerging Paradigm in Stroke Participants. Stroke. 2009;40:510-515. 457 
13. Guzman R, Janowski M, Walczak P. Intra-Arterial Delivery of Cell Therapies for 458 
Stroke. Stroke. 2018;49:1075-1082. 459 
14. Sutherland BA, Neuhaus AA, Couch Y, Balami JS, DeLuca GC, Hadley G, et al. The 460 
transient intraluminal filament middle cerebral artery occlusion model as a model of 461 
endovascular thrombectomy in stroke. J Cereb Blood Flow Metab. 2016;36:363-369. 462 
15. Corbett D, Carmichael ST, Murphy TH, Jones TA, Schwab ME, Jolkkonen J, et al. 463 
Enhancing the Alignment of the Preclinical and Clinical Stroke Recovery Research 464 
Pipeline: Consensus-Based Core Recommendations From the Stroke Recovery and 465 
Rehabilitation Roundtable Translational Working Group. Neurorehabil Neural Repair. 466 
2017;31:699-707. 467 
16. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, et al. Mouse 468 
model of in situ thromboembolic stroke and reperfusion. Stroke. 2007;38:2771-2778. 469 
20 
 
17. Chan SL, Bishop N, Li Z1, Cipolla M. Inhibition of PAI (Plasminogen Activator 470 
Inhibitor)-1 Improves Brain Collateral Perfusion and Injury After Acute Ischemic 471 
Stroke in Aged Hypertensive Rats. Stroke. 2018;49:1969-1976.  472 
18. Boltze J, Förschler A, Nitzsche B, Waldmin D, Hoffmann A, Boltze CM, et al. 473 
Permanent middle cerebral artery occlusion in sheep: a novel large animal model of 474 
focal cerebral ischemia. J Cereb Blood Flow Metab. 2008;28:1951-1964. 475 
19. Werner P, Saur D, Zeisig V, Ettrich B, Patt M, Sattler B, et al. Simultaneous PET/MRI 476 
in stroke: a case series. J Cereb Blood Flow Metab. 2015;35:1421-1425.  477 
20. Hainsworth AH, Allan SM, Boltze J, Cunningham C, Farris C, Head E, et al. 478 
Translational models for vascular cognitive impairment: a review including larger 479 
species. BMC Med. 2017;15:16. 480 
21. Balkaya MG, Trueman RC, Boltze J, Corbett D, Jolkkonen J. Behavioral outcome 481 
measures to improve experimental stroke research. Behav Brain Res. 2018;352:161-482 
171.  483 
22. Cui LL, Kerkelä E, Bakreen A, Nitzsche F, Andrzejewska A, Nowakowski A, et al.  The 484 
cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow 485 
mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell 486 
Res Ther. 2015;6:11.  487 
23. Walczak P, Wojtkiewicz J, Nowakowski A, Habich A, Holak P, Xu J, et al.  Real-time 488 
MRI for precise and predictable intra-arterial stem cell delivery to the central nervous 489 
system. J Cereb Blood Flow Metab. 2017;37:2346-2358. 490 
24. Sommer CJ, Schäbitz WR. Fostering Poststroke Recovery: Towards Combination 491 
Treatments. Stroke. 2017;48:1112-1119. 492 
25. Balseanu AT, Buga AM, Catalin B, Wagner DC, Boltze J, Zagrean AM, et al. 493 
Multimodal Approaches for Regenerative Stroke Therapies: Combination of 494 
21 
 
Granulocyte Colony-Stimulating Factor with Bone Marrow Mesenchymal Stem Cells is 495 
Not Superior to G-CSF Alone. Front Aging Neurosci. 2014;6:130. 496 
26. Pösel C, Scheibe J, Kranz A, Bothe V, Quente E, Fröhlich W, et al. Bone marrow cell 497 
transplantation time-dependently abolishes efficacy of granulocyte colony-stimulating 498 
factor after stroke in hypertensive rats. Stroke. 2014;45:2431-2437. 499 
27. Cui X, Chopp M, Shehadah A, Zacharek A, Kuzmin-Nichols N, Sanberg CD, et al. 500 
Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord 501 
blood cells: neurogenesis, synaptic plasticity, and axon growth. Cell Transplant. 502 
2012;21:845-856. 503 
28. Amer MH, Rose FRAJ, Shakesheff KM, Modo M, White LJ. Translational 504 
considerations in injectable cell-based therapeutics for neurological applications: 505 
concepts, progress and challenges. NPJ Regen Med. 2017;2:23. 506 
29. Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Improving viability of 507 
stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue 508 
Eng Part A. 2012;18:806-815. 509 
30. Nih LR, Carmichael ST, Segura T. Hydrogels for brain repair after stroke: an emerging 510 
treatment option. Curr Opin Biotechnol. 2016;40:155-163. 511 
31.  Moshayedi P, Nih LR, Llorente IL, Berg AR, Cinkornpumin J, Lowry WE, et al. 512 
Systematic optimization of an engineered hydrogel allows for selective control of 513 
human neural stem cell survival and differentiation after transplantation in the stroke 514 
brain. Biomaterials. 2016;105:145-155. 515 
32. Bible E, Dell'Acqua F, Solanky B, Balducci A, Crapo PM, Badylak SF, et al. Non-516 
invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling 517 
in the stroke-damaged rat brain by (19)F- and diffusion-MRI. Biomaterials. 518 
2012;33:2858-2871. 519 
22 
 
33. Nih LR, Sideris E, Carmichael ST, Segura T. Injection of Microporous Annealing 520 
Particle (MAP) Hydrogels in the Stroke Cavity Reduces Gliosis and Inflammation and 521 
Promotes NPC Migration to the Lesion. [published online June 26, 2019]. Adv Mater. 522 
2017. https://onlinelibrary.wiley.com/doi/abs/10.1002/adma.201606471. Accessed 523 
May 28, 2019. 524 
34.  Ghuman H, Massensini AR, Donnelly J, Kim SM, Medberry CJ, Badylak SF, et al. ECM 525 
hydrogel for the treatment of stroke: Characterization of the host cell infiltrate. 526 
Biomaterials. 2016;91:166-181. 527 
35. Bible E, Chau DY, Alexander MR, Price J, Shakesheff KM, Modo M. The support of 528 
neural stem cells transplanted into stroke-induced brain cavities by PLGA particles. 529 
Biomaterials. 2009;30:2985-2994. 530 
36. Conway A, Vazin T, Spelke DP, Rode NA, Healy KE, Kane RS, et al. Multivalent 531 
ligands control stem cell behaviour in vitro and in vivo. Nat Nanotechnol. 2013;8:831-532 
838. 533 
37. Bible E, Qutachi O, Chau DY, Alexander MR, Shakesheff KM, Modo M. Neo-534 
vascularization of the stroke cavity by implantation of human neural stem cells on 535 
VEGF-releasing PLGA microparticles. Biomaterials. 2012;33:7435-7446. 536 
38. Cook DJ, Nguyen C, Chun HN, L Llorente I, Chiu AS, Machnicki M, et al. Hydrogel-537 
delivered brain-derived neurotrophic factor promotes tissue repair and recovery after 538 
stroke. J Cereb Blood Flow Metab. 2017;37:1030-1045. 539 
39. Emerich DF, Silva E, Ali O, Mooney D, Bell W, Yu SJ, et al. Injectable VEGF hydrogels 540 
produce near complete neurological and anatomical protection following cerebral 541 
ischemia in rats. Cell Transplant. 2010;19:1063-1071. 542 
40. Zhang YX, Yuan MZ, Cheng L, Lin LZ, Du HW, Chen RH, et al. Treadmill exercise 543 
enhances therapeutic potency of transplanted bone mesenchymal stem cells in cerebral 544 
ischemic rats via anti-apoptotic effects. BMC Neurosci. 2015;16:56.  545 
23 
 
41. Sasaki Y, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Suzuki J, et al. 546 
Synergic Effects of Rehabilitation and Intravenous Infusion of Mesenchymal Stem Cells 547 
After Stroke in Rats. Phys Ther. 2016;96:1791-1798. 548 
42. Bernhardt J, Borschmann KN, Kwakkel G, Burridge JH, Eng JJ, Walker MF, et al. 549 
Setting the scene for the Second Stroke Recovery and Rehabilitation Roundtable. Int J 550 
Stroke. 2019;14:450-456. 551 
43. Mu J, Bakreen A, Juntunen M, Korhonen P, Oinonen E, Cui L, et al. Combined Adipose 552 
Tissue-Derived Mesenchymal Stem Cell Therapy and Rehabilitation in Experimental 553 
Stroke. Front Neurol. 2019;10:235. 554 
44. Modo MM, Jolkkonen J, Zille M, Boltze J. Future of Animal Modeling for Poststroke 555 
Tissue Repair. Stroke. 2018;49:1099-1106. 556 
45. Kokaia Z, Llorente IL, Carmichael ST. Customized Brain Cells for Stroke Patients 557 
Using Pluripotent Stem Cells. Stroke. 2018;49:1091-1098. 558 
46.  Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs 559 
white populations: a systematic review. Neurology. 2013;81:264-272. 560 
47. Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, et al. Neuronal 561 
Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis 562 
and Necroptosis. Stroke. 2017;48:1033-1043. 563 
48. Ould-Brahim F, Sarma SN, Syal C, Lu KJ, Seegobin M, Carter A, et al. Metformin 564 
Preconditioning of Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells 565 
Promotes Their Engraftment and Improves Post-Stroke Regeneration and Recovery. 566 
Stem Cells Dev. 2018;27:1085-1096. 567 
49. Bernstock JD, Peruzzotti-Jametti L, Ye D, Gessler FA, Maric D, Vicario N, et al. Neural 568 
stem cell transplantation in ischemic stroke: A role for preconditioning and cellular 569 
engineering. J Cereb Blood Flow Metab. 2017;37:2314-2319. 570 
 571 
24 
 
50. Preisig DF, Kulic L, Krüger M, Wirth F, McAfoose J, Späni C, et al. High-speed video 572 
gait analysis reveals early and characteristic locomotor phenotypes in mouse models of 573 
neurodegenerative movement disorders. Behav Brain Res. 2016;311:340-353. 574 
51. Dirnagl U, Fisher M. International, multicenter randomized preclinical trials in 575 
translational stroke research: it's time to act. J Cereb Blood Flow Metab. 2012;32:933-576 
935. 577 
52. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. 578 
Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is 579 
confounded by study quality. Stroke. 2008;39:2824-2829. 580 
53. Boltze J, Ayata C, Wagner DC, Plesnila N. Preclinical phase III trials in translational 581 
stroke research: call for collective design of framework and guidelines. Stroke. 582 
2014;45:357. 583 
54. Boltze J, Wagner DC, Henninger N, Plesnila N, Ayata C. Phase III Preclinical Trials in 584 
Translational Stroke Research: Community Response on Framework and Guidelines. 585 
Transl Stroke Res. 2016;7:241-247. 586 
55. Llovera G, Hofmann K, Roth S, Salas-Pérdomo A, Ferrer-Ferrer M, Perego C, et al. 587 
Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d 588 
treatment for acute brain ischemia. Sci Transl Med. 2015;7:299ra121. 589 
56. Boltze J, Wagner DC, Barthel H, Gounis MJ. Academic-industry Collaborations in 590 
Translational Stroke Research. Transl Stroke Res. 2016;7:343-353. 591 
57. Mays RW, Savitz SI. Intravenous Cellular Therapies for Acute Ischemic Stroke. Stroke. 592 
2018;49:1058-1065. 593 
58. Dirnagl U, Hakim A, Macleod M, Fisher M, Howells D, Alan SM, et al. A concerted 594 
appeal for international cooperation in preclinical stroke research. Stroke. 595 
2013;44:1754-1760. 596 
25 
 
59. Boltze J, Arnold A, Walczak P, Jolkkonen J, Cui L, Wagner DC. The Dark Side of the 597 
Force - Constraints and Complications of Cell Therapies for Stroke. Front Neurol. 598 
2015;6:155. 599 
 600 
 601 
  602 
26 
 
Figure Legends 603 
 604 
Figure 1. Functional improvement by neurorehabilitation and recommended readout 605 
parameters. 606 
(A) Schematic time course of spontaneous functional recuperation (light grey line), 607 
functional improvement with cell therapy alone (grey line), and with additional, appropriately 608 
timed supportive rehabilitation (black line). The relatively small differences between the 609 
therapy groups may require large sample sizes. (B) Behavioral tests differ with respect to 610 
sensitivity and specificity. Simple tests detect relatively large deficits in the acute and subacute 611 
stage. More sensitive tests address particular sensory and motor functions. Elaborated, often 612 
highly automated tests reveal very fine motor and sensory differences, or mental/cognitive 613 
impairment following stroke.  614 
 615 
Figure 2. Proposed concept for accelerated clinical translation.  616 
The basic suggestion of the concept is to initially focus on thorough and advanced safety 617 
assessments. Exploratory (basic) efficacy results warrant entering an early stage, safety-618 
oriented clinical trial (phase I/IIa). This trial should also retrieve important characteristics of 619 
the target patient population, directly informing the design of more advanced, confirmative 620 
preclinical efficacy study (optionally followed by a multicenter preclinical trial) and of tailored 621 
potency assays. Those allow moving forward to clinical efficacy studies (phase IIb/III) tailored 622 
to the expected patient population, but in less time as would be required by sequential research 623 
programs. Regulatory authorities should be consulted regularly to ensure adequate planning of 624 
each parallel step. 625 
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